Despina Fotiou

4.4k total citations
194 papers, 2.5k citations indexed

About

Despina Fotiou is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Despina Fotiou has authored 194 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Hematology, 98 papers in Molecular Biology and 63 papers in Oncology. Recurrent topics in Despina Fotiou's work include Multiple Myeloma Research and Treatments (130 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (54 papers) and Chronic Lymphocytic Leukemia Research (33 papers). Despina Fotiou is often cited by papers focused on Multiple Myeloma Research and Treatments (130 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (54 papers) and Chronic Lymphocytic Leukemia Research (33 papers). Despina Fotiou collaborates with scholars based in Greece, Italy and United States. Despina Fotiou's co-authors include Evangelos Terpos, Meletios Α. Dimopoulos, Efstathios Kastritis, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Magdalini Migkou, Eleni Korompoki, Evangelos Eleutherakis‐Papaiakovou, Θεοδώρα Ψαλτοπούλου and Μαρία Ρούσσου and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Despina Fotiou

172 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Despina Fotiou Greece	25	981	970	716	696	378	194	2.5k
Nicole D. Zantek United States	19	582 0.6×	766 0.8×	303 0.4×	188 0.3×	368 1.0×	67	2.9k
Ennio Giulio Favalli Italy	34	341 0.3×	864 0.9×	278 0.4×	562 0.8×	455 1.2×	138	3.5k
Maria Gavriatopoulou Greece	37	2.2k 2.3×	2.5k 2.6×	2.0k 2.8×	1.0k 1.5×	888 2.3×	376	5.5k
Claudio Sandoval United States	25	784 0.8×	914 0.9×	398 0.6×	93 0.1×	559 1.5×	92	2.8k
Elisa Gremese Italy	35	700 0.7×	718 0.7×	291 0.4×	160 0.2×	306 0.8×	243	4.2k
Laurence Jesel France	33	1.2k 1.2×	401 0.4×	245 0.3×	312 0.4×	79 0.2×	135	3.6k
Mariuca Vasa‐Nicotera Germany	25	1.0k 1.1×	245 0.3×	210 0.3×	845 1.2×	200 0.5×	89	4.6k
Francesca Romana Spinelli Italy	34	511 0.5×	417 0.4×	263 0.4×	201 0.3×	114 0.3×	203	3.3k
Otmar Pfister Switzerland	23	946 1.0×	208 0.2×	399 0.6×	274 0.4×	331 0.9×	76	2.5k
Gian Carlo Avanzi Italy	25	676 0.7×	352 0.4×	357 0.5×	176 0.3×	139 0.4×	92	2.8k

Countries citing papers authored by Despina Fotiou

Since Specialization

Citations

This map shows the geographic impact of Despina Fotiou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Despina Fotiou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Despina Fotiou more than expected).

Fields of papers citing papers by Despina Fotiou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Despina Fotiou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Despina Fotiou. The network helps show where Despina Fotiou may publish in the future.

Co-authorship network of co-authors of Despina Fotiou

This figure shows the co-authorship network connecting the top 25 collaborators of Despina Fotiou. A scholar is included among the top collaborators of Despina Fotiou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Despina Fotiou. Despina Fotiou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eleutherakis‐Papaiakovou, Evangelos, Nikolaos Kanellias, Ioannis Ntanasis‐Stathopoulos, et al.. (2025). The Role of the Bone Marrow Microenvironment in Physical Function and Quality of Life in Patients with Multiple Myeloma After First-Line Treatment with Novel Agents and Autologous Transplantation. SHILAP Revista de lepidopterología. 5(2). 21–21.

Eleutherakis‐Papaiakovou, Evangelos, Magdalini Migkou, Nikolaos Kanellias, et al.. (2025). Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First‐Line Treatment. Scandinavian Journal of Medicine and Science in Sports. 35(2). e70020–e70020.

Terpos, Evangelos, Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, et al.. (2025). Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 145(20). 2353–2360. 5 indexed citations

Ntanasis‐Stathopoulos, Ioannis, Vassilis Koutoulidis, Panagiotis Malandrakis, et al.. (2025). Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice. Journal of Clinical Medicine. 14(7). 2224–2224. 1 indexed citations

Ntanasis‐Stathopoulos, Ioannis, Panagiotis Malandrakis, Despina Fotiou, et al.. (2025). Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience. Clinical Lymphoma Myeloma & Leukemia. 25(12). e1077–e1085.

Ntanasis‐Stathopoulos, Ioannis, Evdoxia Hatjiharissi, Emmanouil Spanoudakis, et al.. (2024). Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group. Blood. 144(Supplement 1). 6988–6988.

Kastritis, Efstathios, Giovanni Palladini, Meletios Α. Dimopoulos, et al.. (2024). Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network. Blood. 144(Supplement 1). 1927–1927.

Terpos, Evangelos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, et al.. (2024). Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.. Journal of Clinical Oncology. 42(16_suppl). 7530–7530. 2 indexed citations

Kostopoulos, Ioannis V., Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, et al.. (2024). Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma. American Journal of Hematology. 99(10). 1887–1896. 4 indexed citations

10.

Malandrakis, Panagiotis, Ioannis V. Kostopoulos, Despina Fotiou, et al.. (2024). Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study. Blood. 144(Supplement 1). 361–361. 2 indexed citations

11.

Terpos, Evangelos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, et al.. (2024). Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma. SHILAP Revista de lepidopterología. 6(1). e889–e889. 1 indexed citations

12.

Fotiou, Despina, et al.. (2023). Photocatalytic removal of the antidepressant fluoxetine from aqueous media using TiO2 P25 and g-C3N4 catalysts. Journal of environmental chemical engineering. 12(1). 111677–111677. 9 indexed citations

13.

Malandrakis, Panagiotis, Ioannis Ntanasis‐Stathopoulos, Ioannis V. Kostopoulos, et al.. (2023). P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY. HemaSphere. 7(S3). e4994547–e4994547. 1 indexed citations

14.

Terpos, Evangelos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, et al.. (2023). Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.. Journal of Clinical Oncology. 41(16_suppl). 8050–8050. 2 indexed citations

15.

Liacos, Christine‐Ivy, Foteini Theodorakakou, Despina Fotiou, et al.. (2023). Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer Journal. 13(1). 31–31. 13 indexed citations

16.

Ntanasis‐Stathopoulos, Ioannis, Panagiotis Malandrakis, Despina Fotiou, et al.. (2023). Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma. International Journal of Molecular Sciences. 24(14). 11829–11829. 9 indexed citations

17.

Kastritis, Efstathios, Maria Gavriatopoulou, Foteini Theodorakakou, et al.. (2023). Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes. Clinical Lymphoma Myeloma & Leukemia. 23(11). 844–849. 6 indexed citations

18.

Terpos, Evangelos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, et al.. (2023). Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial. Blood. 142(Supplement 1). 4765–4765. 2 indexed citations

19.

Fotiou, Despina, Foteini Theodorakakou, & Efstathios Kastritis. (2021). Biomarkers in AL Amyloidosis. International Journal of Molecular Sciences. 22(20). 10916–10916. 11 indexed citations

20.

Gavriatopoulou, Maria, Eleni Korompoki, Despina Fotiou, et al.. (2020). Organ-specific manifestations of COVID-19 infection. Clinical and Experimental Medicine. 20(4). 493–506. 330 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact